In the current study, and in collaboration with Roche Molecular Diagnostics, the cobas® EGFR mutation test (v2) was used for the detection of EGFR sensitizing mutations and the emergence of EGFR exon 20 p.T790M in serial liquid biopsies from patients with EGFR-mutated NSCLC currently receiving EGFR TKIs (cohort 1) or in newly diagnosed treated-naïve patients (cohort 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.